Visium Asset Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Visium Asset Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-608,024	Closed	-$13M	–	515
2016 Q1	$13M	Buy	608,024 +183,024	+43%	+$4.09M	0.22%	114
2015 Q4	$13.4M	Hold	425,000	–	–	0.2%	116
2015 Q3	$14.6M	Buy	+425,000	New	+$12.8M	0.2%	105

Other funds holding MRTX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Visium Asset Management's MRTX Position: Q2 2016 in Review

Visium Asset Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2016, closing a stake of 608,024 shares — an estimated $13M sold.

Visium Asset Management first reported a position in MRTX in Q3 2015 and held it in 3 quarters. The position peaked at $14.6M in Q3 2015. 72 funds tracked by Wall St. Rank hold MRTX as of Q2 2016.

Visium Asset Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
Visium Asset Management sold 608,024 Mirati Therapeutics, Inc. Common Stock shares in Q2 2016, an estimated $13M.
Visium Asset Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2015 and held it in 3 quarters.
Visium Asset Management's Mirati Therapeutics, Inc. Common Stock position peaked at $14.6M in Q3 2015.
72 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2016.

Based on Visium Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.